Engineered Swine Models of Cancer by Adrienne L. Watson et al.
REVIEW
published: 09 May 2016
doi: 10.3389/fgene.2016.00078
Frontiers in Genetics | www.frontiersin.org 1 May 2016 | Volume 7 | Article 78
Edited by:
Lawrence Schook,
University of Illinois, USA
Reviewed by:
Geoff Clark,
University of Louisville, USA
Karine Begnini,






This article was submitted to
Cancer Genetics,
a section of the journal
Frontiers in Genetics
Received: 15 February 2016
Accepted: 18 April 2016
Published: 09 May 2016
Citation:
Watson AL, Carlson DF,
Largaespada DA, Hackett PB and
Fahrenkrug SC (2016) Engineered
Swine Models of Cancer.
Front. Genet. 7:78.
doi: 10.3389/fgene.2016.00078
Engineered Swine Models of Cancer
Adrienne L. Watson 1*, Daniel F. Carlson 1, David A. Largaespada 1, 2, 3, 4, Perry B. Hackett 1, 3, 5
and Scott C. Fahrenkrug 1
1 Recombinetics, St. Paul, MN, USA, 2Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA, 3Genetics,
Cell Biology and Development, University of Minnesota, Minneapolis, MN, USA, 4 Pediatrics, University of Minnesota,
Minneapolis, MN, USA, 5Center for Genome Engineering, University of Minnesota, Minneapolis, MN, USA
Over the past decade, the technology to engineer genetically modified swine has seen
many advancements, and because their physiology is remarkably similar to that of
humans, swine models of cancer may be extremely valuable for preclinical safety studies
as well as toxicity testing of pharmaceuticals prior to the start of human clinical trials.
Hence, the benefits of using swine as a large animal model in cancer research and
the potential applications and future opportunities of utilizing pigs in cancer modeling
are immense. In this review, we discuss how pigs have been and can be used as a
biomedical models for cancer research, with an emphasis on current technologies. We
have focused on applications of precision genetics that can provide models that mimic
human cancer predisposition syndromes. In particular, we describe the advantages of
targeted gene-editing using custom endonucleases, specifically TALENs and CRISPRs,
and transposon systems, to make novel pig models of cancer with broad preclinical
applications.
Keywords: swine models, preclinical cancer models, genetically engineered swine, cancer genetics, genome
engineering
INTRODUCTION
Cancer is the second leading cause of death in the United States. The National Cancer Institute’s
Surveillance, Epidemiology, and End Results (SEER) data, estimated that in 2012 there were more
than 13.7 million people living with cancer in the U.S. (Siegel et al., 2012). Trends suggest that
in 2015 there will be over 1.6 million new cancer diagnoses in the U.S. and a staggering 589,000
deaths due to cancer (SEER). Throughout history there have been dramatic improvements in the
methods by which we detect, diagnose, and treat cancer, yet the 5-year survival for all types of
cancer remains at a dismal 66.5% (N.C.I. Surveillance Research Program; Mukherjee, 2011; Siegel
et al., 2012).While the overall trends in cancer mortality in the U.S. have been reduced over the past
decades, there are still several types of cancer for which the prognosis is very poor and for which few
improvements have been made (Figure 1). Indeed, it has been suggested that the apparent increase
in 5-year survival rates is due to earlier diagnoses, rather than improvements in treatment, for many
types of cancer. The lifetime risk of developing cancer in the U.S. is over 40%, which emphasizes the
need to better understand this deadly disease and improve outcomes for patients diagnosed with
cancer (Siegel et al., 2012).
Cancer is a genetic disease in which cells acquire or inherit mutations, leading to uncontrolled
growth of cells in the blood or solid organs (Hanahan and Weinberg, 2011). Animal models, and
specifically mouse models, have played a major role in our understanding of the genetic basis of
cancer and the role of specific genes and gene mutations in the development and progression of
cancer. Mice led the way for the identification of new therapies to treat cancer owing to advances in
constructing specific mutants in the late 20th century. Hundreds of mouse models of cancer have
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FIGURE 1 | Five-year survival rate based on cancer type. The combined 5-year survival rates of all types of cancer have improved over the past decades, yet
survival for the most deadly types of cancer including esophageal, stomach, liver and intrahepatic bile duct, pancreatic, and lung and bronchial remain very dismal
(www.cancer.gov; N.C.I. Surveillance Research Program).
been made and studied. However, gaining a complete
understanding of cancer, which turns out to be an astonishing
number of variant diseases, and translating this knowledge to
better treatments and ultimately a cure has been elusive. Clearly,
there are limitations to using rodents to model human diseases
including large differences in their size, anatomy, physiology,
drug metabolism, chromosome structures, and their genetics.
Most cancer studies done in mice involve inbred lines of mice
in which every locus is homozygous—a condition that inhibits
translation of murine studies to humans (Hunter, 2012). To
augment studies in the mice, new animal models of cancer
are needed. Swine may turn out to be the best alternative
models due to their size, physiological, genetic, and biochemical
similarities to humans (Prather et al., 2008; Schook et al., 2008;
Ganderup et al., 2012; Swindle et al., 2012; Flisikowska et al.,
2013; Helke and Swindle, 2013). High-throughput genome
sequencing and a collection of precision-genetic tools combined
with tools for bioinformatics analysis, and profiling of gene
expression/proteomics can be applied in swine. The ability
to modify mammalian genomes through transgenesis and
targeted nucleases, united with the development of advanced
reproductive technologies including cloning, allows researchers
to create complex and unique models of cancer in swine that are
more applicable to human disease.
THE LIMITATIONS OF RODENT MODELS
OF CANCER
Due to the vast differences between rodents and humans, the
ability to model the complex diseases such as cancer is quite
limited (Cheng et al., 2014). Humans are 3,000 times larger
than mice, live 30–50 times longer, and therefore undergo about
105 more cell divisions in a lifetime (Rangarajan and Weinberg,
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2003). Without genetic modification, mice develop cancers of
mainly mesenchymal origin, such as sarcomas and lymphomas,
whereas humans have a bias toward the development of epithelial
cancers with age (Rangarajan and Weinberg, 2003). The small
size and short lifespan of mice means that loss of certain tumor
suppressor genes is insufficient to result in development of cancer
in a highly penetrant manner, particularly when such mutations
are heterozygous. Accordingly, investigators have used the Cre-
Lox system to homozygously inactivate tumor suppressors in a
tissue or cell type-specific manner. While this is often sufficient
to drive tumor formation, such a situation does not mimic the
disease course in patients in which rare loss of heterozygosity
(LOH), a genetic condition in which one copy of a gene (or
genetic locus, portion of chromosome, etc.) is lost or deleted
due to a mutation or chromosomal event, occurs in a field of
heterozygous cells. LOH is a common phenomenon in cancer,
resulting in homozygous loss of tumor suppressor genes in a
subset of cells in the body, often leading to the development
of a tumor or the progression of an existing tumor. Because
mouse chromosomes are telocentric, LOH often occurs in mouse
models by loss of the entire chromosome carrying the wild type
tumor suppressor gene allele in cells heterozygous for a tumor
suppressor gene mutation (Luongo and Dove, 1996). However,
in human tumors LOH usually occurs via sub-chromosomal
deletions covering the wild type tumor suppressor gene locus
(Thiagalingam et al., 2001; Petursdottir et al., 2004).
On a cellular level, murine cells have a lower threshold for
genetic and/or epigenetic changes that lead to transformation
in culture, which demonstrates fundamental differences in the
mechanistic properties of cancer development between mice
and humans (Holliday, 1996). Arguably, the most profound
difference between rodent models and humans is the essentially
100% homozygosity of every locus in inbred mouse lines, which
may represent only a single individual in the entire population,
making extrapolation back to entire human populations
challenging (Kaiser, 2015). Mouse cells are immortalized much
more readily than are human cells (Rangarajan and Weinberg,
2003). It has also been suggested that mouse cells respond to
oncogenic Ras expression in a differentmanner than human cells;
RAS oncogenes require RAL signaling in human cells, whereas
the requirement for this signaling pathway is much reduced
in RAS oncogene transformation of mouse cells (Hamad et al.,
2002). Laboratory mouse strains have very long telomeres, and
readily re-express TERT, in contrast to human cells (Holliday,
1996; Kim Sh et al., 2002). Moreover, mice do not develop the
same kinds of genetic instability that human cells do during
tumorigenesis, perhaps due to their shorter lifespan that could
restrict the number of sequential mutations that accumulate in
human tumors (Kim Sh et al., 2002).
Many organ systems vary so greatly between rodents and
humans that certain types of cancer cannot be accurately
modeled. For example, when one copy of the tumor suppressor
gene adenomatous polyposis coli (APC) is inherited in humans,
LOH leads to polyps in the large intestine that progress to
invasive carcinoma. In contrast, mice that are heterozygous for
Apc develop polyps in the small intestine that rarely show disease
progression (Karim and Huso, 2013). Such differences in cancer
development are due to inherent biological differences between
man and rodent and are not limited to the intestinal polyps, but
are seen in many mouse models of cancer (Table 1). There are
fundamental differences in how tumorigenesis occurs in rodents
and humans. This is well illustrated by variations in tumor
spectrum when certain tumor suppressor genes, known to cause
specific cancers in humans, are knocked out in mice (Table 1).
Specifically, the five deadliest cancers in the U.S. (Figure 1) either
cannot be modeled in rodents, or have ineffective models for
identification of treatments that translate to the clinic.
The size limitation in rodents makes the development of novel
imaging modalities and surgical techniques nearly impossible,
yet these are key techniques needed to diagnose and treat a
wide variety of tumor types in patients. Moreover, the rate
of metabolism is much, much higher in mice compared to
humans (Rangarajan and Weinberg, 2003). These differences
mean that the pathways by which tumor progression occurs
can vary dramatically when comparing mouse models to human
cancer. As a consequence, the tumors that develop in a mouse
model may respond differently to therapy. For the genetic
and physiological reasons, including vast differences in drug
metabolism and xenobiotic receptors, rodents also poorly model
toxicity, sensitivity, and efficacy when used in preclinical drug
studies (Swanson et al., 2004). The ability to establish toxicity
and drug sensitivity pre-clinically in animal models is immensely
TABLE 1 | Comparison of knockout mouse models to human patients.
Gene KO mouse Patients References
APC Small intestine polyps which do not typically
progress
Large intestine polyps that progress to invasive carcinoma Groden and Burt, 2012
BRCA1 No cancer development 80% risk of breast cancer, 55% risk of ovarian cancer Evers and Jonkers, 2006
BRCA2 No cancer development 80% risk of breast cancer, 25% risk of ovarian cancer Evers and Jonkers, 2006
NF1 Leukemia, pheochromocytoma Plexiform neurofibromas, malignant peripheral nerve sheath
tumors, optic nerve glioma, astrocytoma, leukemia
Gutmann and Giovannini,
2002
NF2 Bone tumors, lymphoma, lung adenocarcinoma,
hepatocellular carcinoma
Schwannomas, meningiomas, ependymomas Gutmann and Giovannini,
2002
RB Pituitary tumors Retinoblasoma, osteosarcomas, prostate, breast cancer Taneja et al., 2011
TP53 Osteosarcoma, soft tissue sarcoma, lymphoma Breast cancer, brain tumors, osteosarcoma, soft tissue sarcoma Taneja et al., 2011
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important because less than 8% of cancer drugs translate
successfully in Phase I clinical trials from animal models (Mak
et al., 2014). While mice have provided numerous insights into
the biology of cancer, their historical limitations emphasize
the need to develop new models for cancer research, such
as swine.
ADVANTAGES OF USING SWINE CANCER
MODELS
The anatomical, physiological, and genetic similarities between
swine and humans are striking, suggesting that disease modeling
in this large animal may better represent the development and
progression of cancer seen in human patients (Swindle et al.,
2012). Swine have been widely used in many areas of biomedical
research due to such a high resemblance in organ systems. For
these reasons pigs are commonly used in cardiovascular research
where models of atherosclerosis, thrombosis, and myocardial
infarction have been used to understand these health conditions
in patients and to develop therapeutic and medical device
interventions (Dixon and Spinale, 2009; Vilahur et al., 2011). The
similarity in size and anatomy of the swine cardiovascular system
allows design and testing of stents and tissue engineering of blood
vessels (Bedoya et al., 2006; Gyongyosi et al., 2006). Further,
comprehensive studies of the skin, urinary, integumentary, and
digestive systems demonstrate extensive similarities to humans
(Swindle et al., 2012). This history suggests that swine may be
extremely useful as models of human cancer.
Perhaps of greater importance is the degree of genetic
variation in pigs, including those used for disease models.
Numerous genetically distinct lines of pigs exist and are available
for model development, with various levels of diversity and
inbreeding. Cultivation and characterization of these lines
provides the opportunity to address both basic science and
preclinical research needs. Lines that are low in variation provide
a predictable platform for the development of therapeutics
and toxicology research. But, like patients, many swine herds
are highly outbred, with tremendous genetic and phenotypic
heterogeneity that is more reflective of the patient population.
This heterogeneity has two major consequences. First, genes that
act as “drivers” or are otherwise critical to cellular transformation
are more likely to be evident in pigs because they must act
in the presence of other genetic variations. Also, therapeutic
interventions that show efficacy will have to operate in many
genetic environments in pigs, likely more accurately predicting
safety and efficacy in patients.
The swine genome (sus scrofa) has been completely sequenced
and, as expected, it shares considerable homology to the human
genome (Schook et al., 2005; Groenen et al., 2012). Extensive
conservation between pigs and people at the protein and
primary sequence level, and extensive chromosomal synteny
provide opportunities to address the initiation and progression
of cancers, including frequently observed indels, inversions, and
translocations, an outcome prohibitive in rodents, where synteny
is more fragmented (Schook et al., 2005; Groenen et al., 2012).
For instance, one study identified conservation between human
and pigs of 112 loci, wherein a human amino acid that is
implicated in a human disease is the same in swine (Groenen
et al., 2012). Further, gene expression profiling and proteomics
have been rapidly advancing in swine (Garbe et al., 2010).
With the full genomic sequence in swine, the advancement of
bioinformatics tools, the ability to modify somatic swine cells
with transgenesis and targeted nucleases, and the development
of techniques such as somatic cell nuclear transfer (SCNT), we
are now able to create genetically engineered swine models of
human disease (Prather et al., 2008). The homology between
human and swine genes will be a guide for engineering exact
human disease alleles into the swine genome. In the past 4
years, a platform for genetically engineering the swine genome
using targeted nucleases and homology-dependent repair (HDR)
has been developed (Carlson et al., 2012a; Tan et al., 2013).
As described below, this technology allows the replication
of precise amino acid changes and/or truncating mutations
in oncogenes and tumor suppressor genes known to drive
initiation, progression, or metastasis in human cancer. The use
of targeted nucleases to engineer swine genocopies, or exact
mutant alleles that cause cancer in human patients, represent a
more accurate animal model than removing entire exons using
standard knockout strategies or overexpressing oncogenes using
transgenesis, which have been the mainstays in murine models
for decades. Further, recent precision genetic technologies
can support the development of single-gene modifications
and complex, multiple-gene changes as well as chromosomal
translocations in a single generation in swine.
In addition to recent advances in making precise genetic
modifications to large animal genomes, there has been significant
progress in technologies for testing consequences of genetic
changes. Imaging modalities such as computed tomography
(CT), magnetic resonance imaging (MRI), and positron emission
tomography (PET) can be easily applied to large animals such
as pigs, whereas application of analogous clinical protocols is
difficult in rodents (Sieren et al., 2014). By applying these
imaging modalities to swine models of cancer we can improve
detection techniques, better monitor progression, and more
accurately measure response to therapy. The size of the pig allows
for radiation-directed therapies to be tested and optimized.
Surgical resection is the first line of defense and often the
standard of care for many cancers. The size of the pig allows
for refinement of surgical techniques and studies of local
tumor recurrence, both of which are difficult or impossible
to perform in rodents. Tumor natural history is an area that
is difficult to study in rodents due to their short lifespan,
about 1/30th that of humans (Rangarajan and Weinberg, 2003).
Swine can live up to 10 years thereby enabling researchers to
carefully follow the development of tumors, tumor progression,
invasion, and metastasis in the absence of intervention over
time. Additionally, the identification of biomarkers may be
feasible in these animals due to the facile nature of accessing
blood and tissue samples, the abundance of sample material and
the ability to perform longitudinal blood sampling over long
periods of time. Understanding tumor heterogeneity may be well
suited for a large animal, as samples could be collected from
many different tumors over time and followed for variations in
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somatic mutations, gene expression, or differential responses to
treatment.
One of the main drawbacks of rodent models of cancer
has been their inability to identify safe and effective drugs
to treat cancer. Mouse models of cancer have been poor
predictors of drug safety, toxicity, and efficacy (Gould et al.,
2015). Further, routes of administration in mice are largely
limited to intravenous (i.v.), intraperitoneal (i.p.) or oral gavage.
Pigs have been widely used in preclinical drug toxicology, and
are a standard large animal model for preclinical toxicology
prior to human studies (Ganderup et al., 2012). The size and
ease in handling pigs allows for drugs to be administered
in the same way that patients are given them, including
orally, intravenous (i.v.), intraperitoneal (i.p.), inhalation, dermal
absorption, subcutaneous, intramuscular, and transmucosal.
Longitudinal blood sampling can be performed to assess drug
exposure and metabolism over long periods of time, and the
amount of blood samples that can be taken from swine, in a
short period of time, enhances the ability of pharmacologists
to get precise kinetic data following drug exposure. There
is significant homology in xenobiotic receptors in swine and
human that regulate drug metabolism and pharmacokinetic
properties (Myers et al., 2001). The cytochrome P450 (CYP)
superfamily of proteins play a critical role in the processing
and metabolism of drugs, and again, many studies have shown
parallels in the structure and function of these molecules in
pigs and humans (Myers et al., 2001). Importantly for pediatric
cancer drug studies, juvenile pigs have been shown to have
human-similar pharmacokinetic responses to certain drugs that
cannot be modeled in other animals (Roth et al., 2013). The
use of pigs in preclinical drug testing may identify safer and
more effective therapies as well as establish dosing and routes
of administration for new drugs prior to human clinical trials.
Furthermore, a facile porcine genome engineering platform
enables future humanization of drug metabolism in swine
models.
APPLICATIONS OF PRECISION GENETICS
TO MODEL CANCER IN SWINE
There have been three main types of disease models in swine
that have been applied toward cancer modeling—spontaneous,
induced, and genetically modified. Spontaneous models of pig
cancers are rare, because like humans, pigs develop cancer with
age, and as an agricultural animal producedmostly for food, most
pigs do not survive to the age where cancer would be commonly
seen. Sinclair miniature white swine have been a valuable model
of malignant melanoma, which was identified as occurring in
these animals in 1967 and has since been selected for by breeding
(Oxenhandler et al., 1979). Another study identified 92 cases of
leukemia in 3.7 million pigs tested, and 58% of those cases were
in pigs under 6 months of age (Anderson and Jarrett, 1968). A
range of rarer cancers have been described in older pigs (Brown
and Johnson, 1970). However, owing to the economic necessities
of keeping costs low in animals of agricultural importance, pigs
harboring diseases due to rare mutations are euthanized without
further study. Induced models of cancer in swine have been
developed and are providing valuable insights into triggers of
tumorigenesis found in some agricultural environments. In one
study, researchers exposed pigs to N-nitrosodiethylanime to
induce hepatocellular carcinoma (HCC) that resembles human
HCC (Li et al., 2006). Another induced model took advantage
of a naturally occurring severe combined immunodeficiency
(SCID)-like Yorkshire pig line and transplanted human
melanoma and pancreatic carcinoma cells, demonstrating
the usefulness of these animals as human tumor xenografts
(Basel et al., 2012).
Genetic engineering and gene editing technologies are being
developed for cancer modeling in pigs (Figure 2, Table 2).
A transgenic pig carrying the MMTV-v-Ha-ras oncogene was
developed by microinjection of DNA into embryos, although no
tumors developed in these animals (Yamakawa et al., 1999). A
basal cell carcinoma model was created by making a transgenic
pig in which Gli2 was expressed under control of a keratinocyte-
specific promoter (McCalla-Martin et al., 2010). Standard gene-
targeting methods developed in mice have been applied to
pigs and led to the development of a familial adenomatous
polyposis (FAP) model in which gene-targeting was used to
introduce premature termination codons (PTCs) in APC by
electroporation of linearized vector DNA intomesenchymal stem
cells and subsequent SCNT to produce animals (Flisikowska
et al., 2012). Similarly, gene-targeting was used to introduce
a dominant-negative missense mutation, R167H, in the swine
tumor suppressor gene TP53 using a recombinant adeno-
associated virus (rAAV) in fetal fibroblasts, which were cloned
to produce animals that when bred to homozygosity for the
R167H mutation developed lymphomas, osteogenic tumors,
and renal tumors at varying rates (Sieren et al., 2014). These
animals represent a great model for humans with germline
mutant TP53 mutations, seen in Li-Fraumeni patients, as
they develop hematopoietic malignancies, bone tumors, and
adrenal gland tumors in the kidney as well. A breast cancer
model was attempted in the pig using rAAV-mediated BRCA1
knockout, but no phenotype was observed due to death of the
animals by unknown causes before they reached 3 weeks of age
(Luo et al., 2011).
The ability to activate or inactivate genes in a temporal or
spatially-specific manner has been a critical aspect of many
murine models of cancer, and this technology is now being
developed in the pig by use of the Cre-Lox system (Flisikowska
et al., 2013; Schook et al., 2016). There have been three swine
models that use the Cre-Lox system for inducible cancer gene
expression (Leuchs et al., 2012; Li et al., 2015; Schook et al.,
2015). A pig was engineered to harbor a latent TP53R167H
mutation by the insertion of a transcriptional termination signal
between two LoxP sites upstream of the gene, allowing expression
of TP53R167H only in the presence of Cre recombinase. Cre
can be given in a time- or tissue-specific manner to induce
recombination and results in the expression of the dominant
negative TP53 allele, and in the absence of Cre Recombinase,
the latent form of the gene is a knockout; however, at this time,
the effects of this allele in vivo have not been reported (Leuchs
et al., 2012). A second inducible model was generated using
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FIGURE 2 | Methods for developing genetically engineered swine models of cancer. There are three methods for developing genetically engineered swine.
Transgenic swine are created by randomly integrating exogenous DNA into the swine genome, resulting in random insertion and unpredictable expression.
Gene-targeted swine are created using large, homologous DNA sequences to integrate exogenous DNA into the swine genome at targeted loci, but this method has
low efficiency, often requiring the introduction of some exogenous markers such as drug resistance genes. Gene-edited swine are made using designer nucleases,
such as TALENs or CRISPRs, and use a double stranded break at a specific locus to induce efficient homologous recombination to make a targeted alteration in the
genome (Yamakawa et al., 1999; McCalla-Martin et al., 2010; Luo et al., 2011; Flisikowska et al., 2012; Leuchs et al., 2012; Sieren et al., 2014; Li et al., 2015).
TABLE 2 | Genetically engineered swine models of cancer.
Gene Mechanism Method Phenotype References
RAS MMTV-v-Ha-ras transgene Transgenesis No tumor development Yamakawa et al., 1999
GLI2 K5-hGli2 Delta N transgene Transgenesis Basal cell carcinoma-like lesions McCalla-Martin et al., 2010
APC Premature Stop codon at 1311 Gene-targeting by linearized
vector DNA
Low- and high-grade dysplastic
adenomas in large intestine
Flisikowska et al., 2012
APC Premature Stop codon at 1061 Gene-targeting by linearized
vector DNA
No tumor development at 1 year of age Flisikowska et al., 2012
TP53 R167H dominant negative allele Gene-targeting by rAAV Lymphoma and osteogenic tumors Sieren et al., 2014
TP53 R167H dominant negative allele
with floxed termination signal
Gene-targeting by vector DNA TBD Leuchs et al., 2012
BRCA1 Loss of exon 11 Gene-targeting by rAAV Pigs died by 18 days Luo et al., 2011
KRAS Floxed G12D activating allele Gene-targeting by promoter
trap gene targeting vector
TBD Li et al., 2015
KRAS; TP53 Floxed, bicistronic KRASG12D
cDNA and TP53R167H cDNA
Transgenesis Mesenchymal tumor formation upon
AdCre injection
Schook et al., 2015
gene-targeting to express a Cre-activated KRAS G12D mutation,
although the effect of Cre-induced activation of this allele has
yet to be tested in these pigs (Li et al., 2015). Most recently, a
transgenic “oncopig” was developed in which a Cre- inducible
transgene expressingKRAS G12D and TP53 R167H was engineered,
in hopes to model the many types of human cancers that have
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KRAS and TP53 mutations (Schook et al., 2015). Indeed, upon
transgene activation, porcine cells were transformed in culture,
formed tumors in immunodeficient mice, and led to tumors
of mesenchymal origin when activated by AdCre injection
directly into these animals (Schook et al., 2015). In addition
to using the Cre-Lox system for conditional gene expression,
as described in the models above, this system can also be
applied to conditional deletions of short coding sequences and
used as a strategy for inducing chromosomal rearrangements
(Schook et al., 2016).
USING SITE-SPECIFIC NUCLEASES FOR
GENE-EDITING TO MODEL CANCER IN
PIGS
The use of designer nucleases is the latest technological platform
being used to modify the germline of model species. This
technology includes zinc-finger nucleases (ZFNs), transcription
activator-like effector nucleases (TALENs), and clustered
regularly interspaced short palindromic repeats (CRISPRs). All
of these methods to engineer precise changes into genomes have
been used to make genetically engineered mouse models. In
short, site-specific nucleases are designed to bind to user-defined
regions of the DNA. ZFNs utilize a zinc finger domain which
generally contains 3–6 zinc finger repeats recognizing 9–18
base pairs of DNA (Pabo et al., 2001). TALENs utilize a DNA
binding domain contains repeated amino acid sequences,
each which harbors a Repeat Variable Diresidue (RVD) (Boch
et al., 2009). The RVD sequence gives specific nucleotide
recognition, allowing TALENs to bind in a sequence specific
manner (Boch et al., 2009). Typically, both ZFNs and TALENs
utilize a cleavage domain with a bacterial type IIS restriction
endonuclease, FokI, which requires dimerization in order for
DNA cleavage to occur, creating even a higher level of specificity
for site-specific nucleases (Pabo et al., 2001; Boch et al., 2009).
The CRISPR/Cas9 system, derived from the prokaryotic
immune system, consists of guide RNA (gRNA) sequences
that guide Cas9, an RNA-guided DNA endonuclease, which
then cleaves the DNA at these recognition sequences (Jinek
et al., 2012; Mali et al., 2013). All three site-specific nuclease
systems result in a double stranded break in the DNA, which
can be repaired by non-homologous end joining (NHEJ) or
homologous recombination (HR) when a repair template is
provided. NHEJ often results in small insertions and deletions
which can be used to disrupt the function of a gene, where
HR allows users to engineer defined genetic changes at specific
sites within genome (Carlson et al., 2012a,b; Tan et al., 2012,
2013). These genome engineering systems can be applied to
primary cells, which, upon modification, can be used for SCNT
to generate animals with germline genetic changes (Carlson
et al., 2012a; Tan et al., 2012, 2013). Alternatively, these custom
nuclease systems can be applied directly to embryos for in vivo
modification (Bedell et al., 2012; Tan et al., 2012; Lillico et al.,
2013).
The use of custom nucleases to enhance the efficiency of HR
in swine has been dramatic from less than 104 using standard
HR to rates as high as 25–75% using a recently developed
TALEN/homology dependent repair (HDR) platform (Carlson
et al., 2012a; Tan et al., 2013). Our group has used CRISPRs
and TALENs to engineer several pig models of human disease,
including models of infertility and atherosclerosis (Carlson et al.,
2012a; Tan et al., 2013). Despite these advantages, a disadvantage
to using the various site-specific nucleases, is the potential of
undesirable collateral mutations that can accompany those that
are desired (Kim et al., 2013; Lin et al., 2014; Mussolino et al.,
2014; Frock et al., 2015; Hendel et al., 2015). Because the RNA-
guided site-specific platforms (e.g., CRISPR-based) may allow
U-G base-pairing, their fidelity may be lower than the protein-
based platforms (e.g., TALENs). Consequently, although we have
used most of the site-specific nuclease platforms, for fidelity and
efficiency, we find TALEN-induced cleavages are the best balance
for reliable gene-editing (Carlson et al., 2012a; Tan et al., 2013).
TALEN technology allows replication of exact cancer mutations
found in patients in pigs. Indeed, we have used TALENs to
construct a swine models of the cancer predisposition disease,
familial adenomatous polyposis by engineering a premature
termination codon in APC (Tan et al., 2013).
TALEN-based genome editing for making swine genocopies
of human cancer mutations is demonstrated for colorectal
cancer in Figure 3. More generally, for a given type of cancer
or known cancer driver gene, the method begins with the
identification of common mutations within a gene of interest
(Figures 3A,B; Cerami et al., 2012; Gao et al., 2013). Second,
the location of the human mutation must be identified in the
swine gene using bioinformatic approaches in which the amino
acid sequence of the human and swine genes are aligned and
the mutated human amino acid in humans is identified in swine
(Figure 3C; Flicek et al., 2014). Third, custom nucleases such
as TALENs are designed to induce a DSB at the appropriate
site and HDR-oligonucleotides are designed to introduce the
desired mutation (Figures 3D,E; Cermak et al., 2011; Doyle
et al., 2012). We can employ a strategy in which the HDR-
oligo design includes not only the mutation of interest, but a
novel restriction length polymorphism (RFLP) that allows facile
screening of a large number of cells for the desired mutation,
although introduction of a single point mutation in the absence
of an RFLP allele can be engineered as well. Fourth, TALENs
and HDR-oligos are transfected into primary swine fibroblasts,
where they will cut the DNA and induce HDR to introduce
the desired mutation (Figures 3F–H). Transfected cells can be
easily screened by RFLP and sequenced to confirm that the
intended mutation is present (Carlson et al., 2012a; Tan et al.,
2013). In the last step, these cells are used for SCNT to produce
gene-edited swine that have the precise human cancer-causing
mutation. It should be noted that this technology has also be
applied to gene-editing in pig embryos, in addition to somatic
cells, avoiding the need for the somatic cell nuclear transfer
step (Lillico et al., 2013; Whitworth et al., 2014; Wei et al.,
2015).
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FIGURE 3 | Method for TALEN-mediated gene-editing to make a swine colorectal cancer model. (A) The tumor suppressor gene APC is commonly mutated
in colorectal cancer at a rate of 46–91% depending on which study is assessed (Cerami et al., 2012; Gao et al., 2013). The majority of the mutations are mutations
resulting in truncation of APC protein (Cerami et al., 2012; Gao et al., 2013). (B) This figure shows the rate of specific mutations across the APC gene, with truncating
mutations shown in red and missense mutations shown in green (Cerami et al., 2012; Gao et al., 2013). One of the most common mutations in colorectal cancer is an
R876X truncation mutation that was seen in 22/727 mutations analyzed (Cerami et al., 2012; Gao et al., 2013). (C) Human and swine APC genes were aligned and
human exon 16 where R876 is found (shown in blue) aligns with swine amino acid 661 in exon 10 of APC (shown in green) (Flicek et al., 2014). (D) The locus
surrounding swine APC R661 was inputted into software that identified TALENs that would bind and cleave the DNA near this site (TALEN binding sites shown in red;
Cermak et al., 2011; Doyle et al., 2012). (E) A 90mer HDR-oligo was designed with homology upstream and downstream of targeted mutation including the TALEN
binding sites. A C→T base pair change was introduced to create a premature termination codon. Additionally, four nucleotides were added which would cause a
frameshift and a novel RFLP (HindIII) site (shown in green). (F) TALENs and HDR-oligos are then transfected into primary swine fibroblasts. (G) TALENs cut at the
specified location resulting in a double-stranded break (DSB) and the HDR-oligo acts as a template for homologous recombination (HR). (H) HR results in the desired
allele with the novel premature STOP colon, RFLP site, and frameshift incorporated into the genome of the swine fibroblasts (Carlson et al., 2012b; Tan et al., 2013).
UNIQUE OPPORTUNITIES FOR
GENE-EDITED PIG CANCER MODELS
The ability to engineer specific human mutations into the
swine genome is critical for accurately modeling cancer in the
pig. While gene-targeting with either rAAV or other vectors
has the ability to generate animals with swine genocopies of
human disease alleles, these methods generally require the
introduction of exogenous DNA into the swine genome in
the form of antibiotic resistance genes such as puromycin-
or neomycin-resistance since standard gene targeting via HR
in swine is very inefficient with rates less than 1 in 104. In
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contrast, the method of gene editing by employing TALENs
and HDR-oligos of ∼90 nucleotides is highly efficient, with
homologous recombination occurring at an average efficiency of
about 45% across several TALEN pairs tested (Tan et al., 2013).
This allows facile isolation of cellular clones that are heterozygous
or homozygous for the engineered allele of interest.
We identified several types of cancer-causing mutations that
can be engineered into swine using TALEN-mediated gene
editing (Figure 2). Premature STOP codons can be introduced,
resulting in truncated gene products, a common phenomenon for
tumor suppressor genes in cancer (Figure 3). Tumor suppressor
genes have also been shown to contain pointmutations that result
in a dominant negative protein product, as is the case for the
human TP53 mutation R175H, which functions as a dominant
negative in swine (R167H) and can be introduced efficiently using
TALEN-mediated HDR (Leuchs et al., 2012; Sieren et al., 2014).
Similarly, oncogene activation can be modeled by introducing
point mutations such as KRASG12V using TALEN-mediated
HDR. TALEN-mediated gene-editing and HDR repair can be
used to create large deletions encompassing one or more genes,
which are also seen in several types of cancer, such as micro-
deletions of NF1 seen in Neurofibromatosis Type 1 patients
(Pasmant et al., 2010).
In addition tomaking pointmutations using custom nuclease-
mediated HDR, TALENs can be utilized to increase the efficiency
of HDR with much larger constructs such as HDR templates
with homology arms of 750 bp or larger that include LoxP sites
flanking large exons. By inducing a double-stranded break, HDR
occurs at a much higher efficiency than when plasmids or viral
vectors are put into cells alone (Shin et al., 2014). Using TALENs
to induce large HDR events has many applications in developing
swine models of cancer. Many oncogenes and tumor suppressor
genes are somatically mutated and therefore they must be
expressed or disrupted in specific tissue types, at specific times.
Using custom nuclease-mediated HDR, one could introduce
LoxP flanked exons of tumor suppressor genes, or introduce
latent oncogenes that would need to be activated by Cre-
recombinase to support tissue/temporal regulation. This method
allows for the introduction of transgenes at specific loci in
the genome thereby avoiding unwanted insertional mutagenesis
effects. In order to introduce multiple genetic changes that occur
in cancer, TALEN-mediated, site-specific mutagenesis can be
used to introduce simultaneous targeted disruption of a tumor
suppressor gene along with one or more transgenes for oncogene
expression.
The ability to edit multiple genes at one time is necessary due
to multiple genetic alterations in each cancer cell. The efficiency
at which the TALEN-mediated gene-editing and small HDR-
oligo platform works, allows this technology to be applied toward
multiplex gene-editing to model more complex genotypes of
human tumors. Epidemiological data and mathematical models
in colorectal cancer has suggested that it takes about five to seven
rate limiting “steps” for transformation to occur (Renan, 1993).
More recently, whole exome sequencing analysis in colorectal
and breast cancer has shown that tumors have an average of 90
mutant genes, with 11 of these mutations being “cancer-causing”
(Sjoblom et al., 2006). There are many types of cancer for
which mutations in two or more genes are clearly demonstrated
(Figure 4; Cerami et al., 2012; Gao et al., 2013). Recapitulating
this phenomenon would be ideal when engineering animal
models of cancer. Developing these multi-hit models is virtually
impossible by standard gene-targeting techniques due to such
low efficiencies, and would therefore require either serial cloning
or animal breeding to obtain multiple alleles in one animal. Both
of these alternatives are expensive and time-consuming in large
animals such as swine. In contrast, the efficient custom nuclease-
stimulated HDR allows the engineering of multiple cancer genes
in a single generation.
Multiplex gene editing can also be applied in making models
of cancer with associated co-morbidities. Treating patients with
cancer becomes quite complex when the patient is suffering from
other diseases as well, and this phenomenon of co-morbidity is
quite common (Table 3; Sogaard et al., 2013). A study of 15,962
patients showed various types of cancers that are more highly
associated with comorbidities (Ogle et al., 2000). The overall
frequency of any single comorbidity occurring in this population
of cancer patients was 68.7% and 32.6% of patients had two
or more comorbidities (Ogle et al., 2000). Some of the effects
of these comorbidities on cancer patients and their subsequent
survival and cancer treatment are shown in Table 3 (Sogaard
et al., 2013). Several studies have demonstrated that patients with
comorbidities are less likely to complete chemotherapy, more
likely to suffer complications from treatment and/or surgery,
and the 5-year mortality hazard ratio for cancer patients with
comorbidities ranges from 1.1 up to 5.8 (Sogaard et al., 2013).
A multiplex gene editing approach can be taken to model
complex disease associations with cancer to understand the
impact on survival and treatment approaches. For example, we
have used our gene-editing technology to develop swine models
of hypercholesterolemia, heart failure, and hypertension and
have the ability to generate models of various cancer types in
conjunction with these common comorbidities (Carlson et al.,
2012a; Tan et al., 2013). Using multiplex gene-editing, it is
possible to engineer swine models of cancer in the background
of other comorbidity diseases in a single generation.
Genomic rearrangements, and specifically, chromosomal
translocations are a common occurrence in cancer (Table 4)
(Nambiar et al., 2008). The ability to model cancer-causing
translocations has been limited to the expression of gene-
fusion transgenes in mice and has yet to be demonstrated
in swine. Chromosomal translocations can be induced by
double-stranded DNA breaks and TALEN technology allows
engineering of exact human translocations at endogenous loci
in the swine genome resulting in expression from the native
promoter (Figure 5). Indeed, cancer translocations have been
previously engineered using TALENs and ZFNs in human cells
(Piganeau et al., 2013) and could also be applied in porcine
cells. Applying TALEN-mediated site-specific mutagenesis to
swine opens up a broad field of new research into the
mechanism of oncogene activation via genomic rearrangements,
the pathogenicity of chromosomal translocations in various
cancer types, and investigations into therapies targeting novel
gene-fusions and mechanisms of resistance in translocation-
driven cancer types.
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FIGURE 4 | Commonly co-mutated genes in colorectal adenocarcinoma and glioblastoma multiforme. (A) A study of 220 colorectal adenocarcinoma cases
found that 73% of cases had APC mutations and 54% of cases had TP53 mutations. Forty-six percent of cases had both APC and TP53 mutations. (B) Similarly, in
109 cases of glioblastoma multiforme (GBM), 14% of cases has NF1 mutations and 30% has TP53 mutations. 8% of cases had both NF1 and TP53 mutations.
(C) The types of mutations seen in APC and TP53 in colorectal cancer (top) and GBM (bottom). Because all of these genes are tumor suppressor genes, the majority
of mutations are truncating mutations or missense mutations (Cerami et al., 2012; Gao et al., 2013).
PIGS AS MODELS FOR CANCER
XENOGRAFTS
An additional application of TALEN-based multiplex gene
editing is the ability to simultaneously knock out and add in
genes involved in immune system development to facilitate even
a broader range of cancer research applications. We and others
have developed a severe combined immunodeficiency (SCID)
swine model by knocking out genes necessary for both B-cell
and T-cell development (Figure 6) (Shultz et al., 2007; Suzuki
et al., 2012; Watanabe et al., 2013; Huang et al., 2014; Ito
et al., 2014). These animals will allow xenograft experiments
to proceed in which one could engraft cells or tissues from
human tumors into the pig and monitor these xenografts for
growth and development properties, as well as for efficacy studies
with novel therapies. These animals can also be engrafted with
human immune cells by either blastocyst complementation or
transplantation, making a “humanized pig.” This animal would
serve several purposes including to investigate the role of the
immune system in response to chemo- and radio-therapies for
the treatment of cancer and the role of the human immune
system in cancer development and progression if combined
with a tumor xenograft (Zitvogel et al., 2011). These animals
may also have a major impact on immunological research and
treatments including the evaluation of: (1) immune-modulatory
drugs (Pardoll, 2012; Ileana et al., 2013), (2) cell-based therapies
(Fischbach et al., 2013), (3) adoptive T-cell transfer (June, 2007),
(4) autologous immune enhancement therapy (Rosenberg, 1984),
(5) genetically engineered T-cells (Restifo et al., 2012), and (6)
studies of inflammation and infectious disease in the context of
cancer (Cibelli et al., 2013).
An alternative approach to using swine as cancer xenograft
models is by a method called in utero cell transplantation (Fisher
et al., 2013). This method relies on the ability of a fetus to become
tolerized to foreign antigens by exposing an immunologically
immature fetus to xenogenic cells (Fisher et al., 2013). This allows
the recipient fetus to recognize human cells as “self,” when the
foreign cells are injected prior to population of the pig thymus
by CD3+ lymphocytes (Sinkora et al., 2000). This approach
has allowed stable and long-term engraftment of both allogenic
and xenogenic cells into immunocompetent host animals (Flake
et al., 1986; Zanjani et al., 1992a,b, 1994). Using this method,
one could perform in utero injections of a xenograft cell line of
interest, tolerizing the host pig, and allowing for engraftment
of human cancer cells in the pig post-natally. The xenogenic
cells could be established human cancer cell lines, or human
cells engineered with specific mutations and/or transgenes to
determine their contribution to tumor formation, tumor growth,
or drug responsiveness.
APPLYING TRANSPOSON SYSTEMS IN
PIGS TO STUDY CANCER DEVELOPMENT,
PROGRESSION, IMMUNE RESPONSE,
AND DRUG RESISTANCE
Transposable elements have been widely used in in forward
genetic screens to identify genes involved in cancer, as well as
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Cardiovascular Disease (CVD) Urinary bladder 31.2 • Chemotherapy and radiation can worsen CVD
Stomach 30.3 • Chemotherapy has cardiotoxic effects
Lung 30.1 • Concerns with bleeding and thrombocytopenia in patients with stents
or prosthetic valves may complicate treatmentAll sites 28.9
Diabetes Liver 12.7 • Diabetes significantly increases mortality in cancer patients
Eye 10.1 • Steroids given with chemotherapy can elevate glucose levels
Mesothelioma 8.5
All sites 6.1
Hypertension Colon 46.8 • Hypertension results in an overall higher risk of cancer death
Eye 44.5 • Hypertension puts patients at risk during surgery and radiation
therapy for hypertensive crisisStomach 43.5
All sites 41.2 • Chemotherapy and some targeted therapies can increase
hypertension
Respiratory Disease Lung 37.1 • Increased odds of complications with cancer
Mesothelioma 31.8 • Patients less likely to undergo surgery
Esophagus 25.1
All sites 25.1
Cerebrovascular disease Stomach 10.0 • Development of cerebrovascular disease may be provoked by cancer
treatmentLung 9.1
Esophagus 8.5 • Endothelium toxicity and abnormalities of coagulation factors with
chemotherapy can induce strokeAll sites 7.9
Any single comorbidity All cancers 68.7
Any two comorbidities All cancers 32.6
TABLE 4 | Common cancer-associated chromosomal translocations
(Nambiar et al., 2008).
Cancer type Translocation Human location Pig location
Burkitt’s lymphoma c-myc IGH@ t(8;14)(q24;q32) t(4;1)
Follicular thyroid cancer PAX8 PPARg1 t(2;3)(q13;p25) t(2;1)
Acute myeloblastic
leukemia




ABL1 BCR t(9;22)(q34;q11) t(1;14)
Ewing’s sarcoma FLI1 EWS t(11;22)(q24;q11.2−12) t(9;14)
in reverse genetic studies to produce transgenic animals and
determine the contribution a gene or set of genes makes in
the development of cancer (Tschida et al., 2014). Transgenesis
via transposon systems have produced transgenic mice, rats,
fish, frogs, and more recently, pigs (Clark et al., 2007; Carlson
et al., 2011; Garrels et al., 2011; Jakobsen et al., 2011). Using
cytoplasmic or pronuclear injection, transposon systems can
efficiently deliver genes of interest into the porcine genome,
allowing for the development of transposon-mediated transgenic
porcine cancer models (Carlson et al., 2011; Garrels et al., 2011).
Another application of transposon systems in swine is to
utilize the ability of transposon mutagenesis systems to screen
for genes involved in cancer. Historically, these studies have
been done in mice in which one chromosome contains a
concatemer of transposons, and upon expression of transposase,
these transposons randomly integrate throughout the genome
(Moriarity and Largaespada, 2015). By random chance, certain
cells will have the right combination of oncogenes activated
and/or tumor suppressor genes inactivated to cause a tumor to
form (Moriarity and Largaespada, 2015). These studies depend
on the development of many, many tumors, which are then
sequenced to determine genes that were activated or inactivated
by transposon mutagenesis (Moriarity and Largaespada, 2015).
Bioinformatics analysis can predict which genes are potential
drivers in the development of cancer, because they will undergo
mutagenesis at a rate higher than would be expected by random
chance (Moriarity and Largaespada, 2015).
The pig offers unique opportunities for applying transposon
mutagenesis screens. For example, due to the large size of the
pig, one could engineer a swine model harboring transposon
concatemers and expressing a transposase, and look for tumors
by imaging using MRI, CT, PET, or ultrasound analysis. By
using sophisticated imaging techniques, coupled with the large
size of the pig and availability of tissue samples, one could
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FIGURE 5 | TALEN-induced translocations. TALEN technology can be applied for inducing targeted translocations in the swine genome. In this example, a
translocation event is known to cause the BCR-ABL1 fusion gene resulting in chronic myelogenous leukemia. A TALEN pair is designed to cut at the known breakpoint
in the BCR gene and a second TALEN is designed to cut at the known breakpoint in ABL1 gene. When these two double stranded breaks occur simultaneously,
chromosomal repair will induce a targeted translocation and result in the expression of the BCR-ABL1 fusion gene at the endogenous loci in the swine genome.
biopsy tumors, and look at transposon insertion sites over time
to determine tumor evolution genes involved in development,
progression, and metastasis (DeNicola et al., 2015). Further,
pigs that develop tumors could be treated with drugs, and
their tumors monitored over time to look for tumor regression
followed by development of resistance. Tumors that show initial
regression to a certain drug could be sequenced to identify
genes involved in drug sensitivity. Similarly, tumors that develop
resistance to a drug or therapy could be sequenced to identify
genes involved in the development of drug resistance. Lastly, new
and innovative applications of transposon mutagenesis screens
can be applied to swine models of cancer. For example, as
described previously, the Sinclair miniature white pig develops
a spontaneous form of malignant melanoma (Oxenhandler
et al., 1979). Interestingly, these pigs show a nearly 100%
spontaneous regression of cutaneous melanomas (Oxenhandler
et al., 1982). This spontaneous development and regression
of melanoma model is a perfect opportunity to utilize a
transposon mutagenesis system to identify genes involved in
the suppression of regression. Lastly, methods for transposon-
mediated transgene delivery to somatic cells have been developed
in the mouse and could be applied in the pig as well (Wiesner
et al., 2009).
PIG MODELS OF CANCER: UNANSWERED
QUESTIONS AND LOOKING FORWARD
Cancer remains the second leading cause of death in the U.S.
There is a chronic need to understand the etiology and biology
of this collection of diseases as well as identify new treatments.
The anatomical, physiological, and genetic variations between
mice and humans limit the prospects of meeting the needs of
patients by modeling cancer in rodents. However, for any novel
animal model to be useful in cancer research, it must be adopted
and fully tested in many laboratories under many circumstances.
Even though pigs may turn out to be better models to investigate
cancer and potential therapeutics, the considerable expense
associated with large animals over their extended lifetimes
coupled with the perceived need to run experiments under
various experimental and controlled conditions may impede the
rate of their widespread adoption into mainstream science. That
will be determined by the scientific community plus funding
and private entities that support cancer research and therapeutic
development. As a large animal with striking similarities in
anatomical structure, physiological function, and genetic makeup
to humans, we expect the pig will become an improved model
animal to advance decades of cancer research studies conducted
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FIGURE 6 | Immunodeficient swine for cancer research. (A) RAG2 and IL2Rg function in the development of B cells, T cells, and Natural Killer (NK) cells. When
both of these genes are mutated, the resulting organism lacks both the innate and adaptive immune system function (Shultz et al., 2007). (B) An IL2Rg/RAG2
knockout pig to model SCID has many practical applications for cancer research.
in rodents. Custom endonucleases, such as TALENs, coupled
with cloning, enable the engineering of swine genocopies of
human cancers mutations, providing a myriad of unique and
exciting opportunities in cancer research that may ultimately
better model cancer seen in human patients and lead to novel
biological insights into the mechanism of cancer and more
effective treatments for patients.
AUTHOR CONTRIBUTIONS
AW provided intellectual content and drafted the review
article, figures and tables. DC, DL, PH, and SF contributed
significant ideas and intellectual content including
conception and design and provided critical review and
editing.
REFERENCES
Anderson, L. J., and Jarrett, W. F. (1968). Lymphosarcoma (Leukemia) in cattle,
sheep and pigs in Great Britain. Cancer 22, 398–405.
Basel, M. T., Balivada, S., Beck, A. P., Kerrigan, M. A., Pyle, M. M., Dekkers, J.
C., et al. (2012). Human xenografts are not rejected in a naturally occurring
immunodeficient porcine line: a human tumor model in pigs. Biores. Open
Access 1, 63–68. doi: 10.1089/biores.2012.9902
Bedell, V. M., Wang, Y., Campbell, J. M., Poshusta, T. L., Starker, C.
G., Krug, R. G. II, et al. (2012). In vivo genome editing using a
high-efficiency talen system. Nature 491, 114–118. doi: 10.1038/nature
11537
Bedoya, J., Meyer, C. A., Timmins, L. H., Moreno, M. R., and Moore, J. E. (2006).
Effects of stent design parameters on normal artery wall mechanics. J. Biomech.
Eng. 128, 757–765. doi: 10.1115/1.2246236
Boch, J., Scholze, H., Schornack, S., Landgraf, A., Hahn, S., Kay, S.,
et al. (2009). Breaking the code of DNA binding specificity of Tal-
Type Iii effectors. Science 326, 1509–1512. doi: 10.1126/science.11
78811
Brown, D. G., and Johnson, D. F. (1970). Diseases of aged swine. J. Am. Vet. Med.
Assoc. 157, 1914–1918.
Carlson, D. F., Fahrenkrug, S. C., and Hackett, P. B. (2012b). Targeting DNA with
fingers and talens.Mol. Ther. Nucleic Acids 1, e3. doi: 10.1038/mtna.2011.5
Carlson, D. F., Garbe, J. R., Tan, W., Martin, M. J., Dobrinsky, J. R., Hackett, P.
B., et al. (2011). Strategies for selection marker-free swine transgenesis using
the sleeping beauty transposon system. Transgenic Res. 20, 1125–1137. doi:
10.1007/s11248-010-9481-7
Carlson, D. F., Tan, W., Lillico, S. G., Stverakova, D., Proudfoot, C., Christian, M.,
et al. (2012a). Efficient talen-mediated gene knockout in livestock. Proc. Natl.
Acad. Sci. U.S.A. 109, 17382–17387. doi: 10.1073/pnas.1211446109
Frontiers in Genetics | www.frontiersin.org 13 May 2016 | Volume 7 | Article 78
Watson et al. Engineered Swine Models of Cancer
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., et al.
(2012). The Cbio cancer genomics portal: an open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2, 401–404. doi:
10.1158/2159-8290.CD-12-0095
Cermak, T., Doyle, E. L., Christian, M., Wang, L., Zhang, Y., Schmidt, C.,
et al. (2011). Efficient design and assembly of custom talen and other Tal
effector-based constructs for DNA targeting. Nucleic Acids Res. 39, e82. doi:
10.1093/nar/gkr739
Cheng, Y., Ma, Z., Kim, B. H., Wu, W., Cayting, P., Boyle, A. P.,
et al. (2014). Principles of Regulatory Information Conservation
between Mouse and Human. Nature 515, 371–375. doi: 10.1038/nature
13985
Cibelli, J., Emborg, M. E., Prockop, D. J., Roberts, M., Schatten, G., Rao, M., et al.
(2013). Strategies for improving animal models for regenerative medicine. Cell
Stem Cell 12, 271–274. doi: 10.1016/j.stem.2013.01.004
Clark, K. J., Carlson, D. F., and Fahrenkrug, S. C. (2007). Pigs taking wing with
transposons and recombinases. Genome Biol. 8(Suppl. 1):S13. doi: 10.1186/gb-
2007-8-s1-s13
DeNicola, G. M., Karreth, F. A., Adams, D. J., and Wong, C. C. (2015). The utility
of transposon mutagenesis for cancer studies in the era of genome editing.
Genome Biol. 16, 229. doi: 10.1186/s13059-015-0794-y
Dixon, J. A., and Spinale, F. G. (2009). Large animal models of heart failure: a
critical link in the translation of basic science to clinical practice. Circ. Heart
Fail. 2, 262–271. doi: 10.1161/CIRCHEARTFAILURE.108.814459
Doyle, E. L., Booher, N. J., Standage, D. S., Voytas, D. F., Brendel, V. P., Vandyk,
J. K., et al. (2012). Tal Effector-Nucleotide Targeter (Tale-Nt) 2.0: tools for Tal
effector design and target prediction. Nucleic Acids Res. 40, W117–W122. doi:
10.1093/nar/gks608
Evers, B., and Jonkers, J. (2006). Mouse models of Brca1 and Brca2 deficiency: past
lessons, current understanding and future prospects. Oncogene 25, 5885–5897.
doi: 10.1038/sj.onc.1209871
Fischbach, M. A., Bluestone, J. A., and Lim, W. A. (2013). Cell-based
therapeutics: the next pillar of medicine. Sci. Transl. Med. 5, 179ps7. doi:
10.1126/scitranslmed.3005568
Fisher, J. E., Lillegard, J. B., McKenzie, T. J., Rodysill, B. R., Wettstein, P. J., and
Nyberg, S. L. (2013). In utero transplanted human hepatocytes allow postnatal
engraftment of human hepatocytes in pigs. Liver Transpl. 19, 328–335. doi:
10.1002/lt.23598
Flake, A. W., Harrison, M. R., Adzick, N. S., and Zanjani, E. D. (1986).
Transplantation of fetal hematopoietic stem cells in utero: the creation
of hematopoietic chimeras. Science 233, 776–778. doi: 10.1126/science.28
74611
Flicek, P., Amode, M. R., Barrell, D., Beal, K., Billis, K., Brent, S., et al.
(2014). Ensembl 2014. Nucleic Acids Res. 42, D749–D755. doi: 10.1093/nar/gk
t1196
Flisikowska, T., Kind, A., and Schnieke, A. (2013). The new pig on the block:
modelling cancer in pigs. Transgenic Res. 22, 673–680. doi: 10.1007/s11248-
013-9720-9
Flisikowska, T., Merkl, C., Landmann, M., Eser, S., Rezaei, N., Cui, X., et al.
(2012). A porcine model of familial adenomatous polyposis. Gastroenterology
143, 1173-5.e1–7. doi: 10.1053/j.gastro.2012.07.110
Frock, R. L., Hu, J., Meyers, R. M., Ho, Y. J., Kii, E., and Alt, F. W. (2015). Genome-
wide detection of DNA double-stranded breaks induced by engineered
nucleases. Nat. Biotechnol. 33, 179–186. doi: 10.1038/nbt.3101
Ganderup, N. C., Harvey, W., Mortensen, J. T., and Harrouk, W. (2012). The
minipig as nonrodent species in toxicology–where are we now? Int. J. Toxicol.
31, 507–528. doi: 10.1177/1091581812462039
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., et al.
(2013). Integrative analysis of complex cancer genomics and clinical profiles
using the cBioPortal. Sci. Signal. 6:pl1. doi: 10.1126/scisignal.2004088
Garbe, J. R., Elsik, C. G., Antoniou, E., Reecy, J. M., Clark, K. J., Venkatraman,
A., et al. (2010). Development and application of bovine and porcine
oligonucleotide arrays with protein-based annotation. J. Biomed. Biotechnol.
2010:453638. doi: 10.1155/2010/453638
Garrels, W., Mates, L., Holler, S., Dalda, A., Taylor, U., Petersen, B., et al.
(2011). Germline transgenic pigs by sleeping beauty transposition in porcine
zygotes and targeted integration in the pig genome. PLoS ONE 6:e23573. doi:
10.1371/journal.pone.0023573
Gould, S. E., Junttila, M. R., and de Sauvage, F. J. (2015). Translational value of
mouse models in oncology drug development. Nat. Med. 21, 431–439. doi:
10.1038/nm.3853
Groden, J., and Burt, R. (2012). Genotypes and phenotypes: animal models of
familial adenomatous polyposis coli. Gastroenterology 143, 1133–1135. doi:
10.1053/j.gastro.2012.09.023
Groenen, M. A., Archibald, A. L., Uenishi, H., Tuggle, C. K., Takeuchi,
Y., Rothschild, M. F., et al. (2012). Analyses of pig genomes provide
insight into porcine demography and evolution. Nature 491, 393–398. doi:
10.1038/nature11622
Gutmann, D. H., and Giovannini, M. (2002). Mouse models of neurofibromatosis
1 and 2. Neoplasia 4, 279–290. doi: 10.1038/sj.neo.7900249
Gyongyosi, M., Strehblow, C., Sperker, W., Hevesi, A., Garamvolgyi, R., Petrasi,
Z., et al. (2006). Platelet activation and high tissue factor level predict acute
stent thrombosis in pig coronary arteries: prothrombogenic response of drug-
eluting or bare stent implantation within the first 24 hours. Thromb. Haemost.
96, 202–209. doi: 10.1160/TH06-03-0178
Hamad, N. M., Elconin, J. H., Karnoub, A. E., Bai, W., Rich, J. N., Abraham, R. T.,
et al. (2002). Distinct requirements for ras oncogenesis in human versus mouse
cells. Genes Dev. 16, 2045–2057. doi: 10.1101/gad.993902
Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next
generation. Cell 144, 646–674. doi: 10.1016/j.cell.2011.02.013
Helke, K. L., and Swindle, M. M. (2013). Animal models of toxicology testing:
the role of pigs. Expert Opin. Drug Metab. Toxicol. 9, 127–139. doi:
10.1517/17425255.2013.739607
Hendel, A., Fine, E. J., Bao, G., and Porteus, M. H. (2015). Quantifying
on- and off-target genome editing. Trends Biotechnol. 33, 132–140. doi:
10.1016/j.tibtech.2014.12.001
Holliday, R. (1996). Neoplastic transformation: the contrasting stability of human
and mouse cells. Cancer Surv. 28, 103–115.
Huang, J., Guo, X., Fan, N., Song, J., Zhao, B., Ouyang, Z., et al. (2014). RAG1/2
knockout pigs with severe combined immunodeficiency. J. Immunol. 193,
1496–1503. doi: 10.4049/jimmunol.1400915
Hunter, K. W. (2012). Mouse models of cancer: does the strain matter? Nat. Rev.
Cancer 12, 144–149. doi: 10.1038/nrc3206
Ileana, E., Champiat, S., and Soria, J. C. (2013). [Immune-checkpoints:
the new anti-cancer immunotherapies]. Bull. Cancer 100, 601–610. doi:
10.1684/bdc.2013.1771
Ito, T., Sendai, Y., Yamazaki, S., Seki-Soma, M., Hirose, K., Watanabe, M. (2014).
Generation of recombination activating gene-1-deficient neonatal piglets: a
model of T and B cell deficient severe combined immune deficiency. PLoS ONE
9:e113833. doi: 10.1371/journal.pone.0113833
Jakobsen, J. E., Li, J., Kragh, P. M., Moldt, B., Lin, L., Liu, Y., et al. (2011).
Pig transgenesis by sleeping beauty DNA transposition. Transgenic Res. 20,
533–545. doi: 10.1007/s11248-010-9438-x
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., and Charpentier,
E. (2012). A programmable dual-Rna-guided DNA endonuclease in adaptive
bacterial immunity. Science 337, 816–821. doi: 10.1126/science.1225829
June, C. H. (2007). Adoptive T cell therapy for cancer in the clinic. J. Clin. Invest.
117, 1466–1476. doi: 10.1172/jci32446
Kaiser, J. (2015). The cancer test. Science 348, 1411–1413. doi:
10.1126/science.348.6242.1411
Karim, B. O., and Huso, D. L. (2013). Mouse models for colorectal cancer. Am. J.
Cancer Res. 3, 240–250. doi: 10.1053/j.gastro.2008.12.049
Kim, Y., Kweon, J., and Kim, J. S. (2013). Talens and Zfns are associated with
different mutation signatures. Nat. Methods 10, 185. doi: 10.1038/nmeth.2364
Kim Sh, S. H., Kaminker, P., and Campisi, J. (2002). Telomeres, aging and cancer:
in search of a happy ending.Oncogene 21, 503–511. doi: 10.1038/sj.onc.1205077
Leuchs, S., Saalfrank, A., Merkl, C., Flisikowska, T., Edlinger, M., Durkovic, M.,
et al. (2012). Inactivation and inducible oncogenic mutation of P53 in gene
targeted pigs. PLoS ONE 7:e43323. doi: 10.1371/journal.pone.0043323
Li, S., Edlinger, M., Saalfrank, A., Flisikowski, K., Tschukes, A., Kurome, M., et al.
(2015). Viable pigs with a conditionally-activated oncogenic kras mutation.
Transgenic Res. 24, 509–517. doi: 10.1007/s11248-015-9866-8
Li, X., Zhou, X., Guan, Y., Wang, Y. X., Scutt, D., and Gong, Q. Y. (2006).
N-nitrosodiethylamine-induced pig liver hepatocellular carcinoma model:
radiological and histopathological studies. Cardiovasc. Intervent. Radiol. 29,
420–428. doi: 10.1007/s00270-005-0099-8
Frontiers in Genetics | www.frontiersin.org 14 May 2016 | Volume 7 | Article 78
Watson et al. Engineered Swine Models of Cancer
Lillico, S. G., Proudfoot, C., Carlson, D. F., Stverakova, D., Neil, C., Blain, C., et al.
(2013). Live pigs produced from genome edited zygotes. Sci. Rep. 3:2847. doi:
10.1038/srep02847
Lin, Y., Cradick, T. J., Brown, M. T., Deshmukh, H., Ranjan, P., Sarode, N.,
et al. (2014). Crispr/Cas9 systems have off-target activity with insertions or
deletions between target DNA and guide Rna sequences. Nucleic Acids Res. 42,
7473–7485. doi: 10.1093/nar/gku402
Luo, Y., Li, J., Liu, Y., Lin, L., Du, Y., Li, S., et al. (2011). High efficiency of Brca1
knockout using raav-mediated gene targeting: developing a pigmodel for breast
cancer. Transgenic Res. 20, 975–988. doi: 10.1007/s11248-010-9472-8
Luongo, C., and Dove, W. F. (1996). Somatic genetic events linked to the Apc
Locus in intestinal adenomas of the min mouse. Genes Chromosomes Cancer
17, 194–198.
Mak, I. W., Evaniew, N., and Ghert, M. (2014). Lost in translation: animal models
and clinical trials in cancer treatment. Am. J. Transl. Res. 6, 114–118.
Mali, P., Esvelt, K. M., and Church, G. M. (2013). Cas9 as a versatile tool for
engineering biology. Nat. Methods 10, 957–963. doi: 10.1038/nmeth.2649
McCalla-Martin, A. C., Chen, X., Linder, K. E., Estrada, J. L., and Piedrahita,
J. A. (2010). Varying phenotypes in swine versus murine transgenic models
constitutively expressing the same human sonic hedgehog transcriptional
activator, K5-Hgli2 Delta N. Transgenic Res. 19, 869–887. doi: 10.1007/s11248-
010-9362-0
Moriarity, B. S., and Largaespada, D. A. (2015). Sleeping beauty transposon
insertional mutagenesis based mouse models for cancer gene discovery. Curr.
Opin. Genet. Dev. 30, 66–72. doi: 10.1016/j.gde.2015.04.007
Mukherjee, S., (2011). The Emperor of All Maladies: A Biography of Cancer. New
York, NY: Scribner.
Mussolino, C., Alzubi, J., Fine, E. J., Morbitzer, R., Cradick, T. J., Lahaye, T.,
et al. (2014). Talens facilitate targeted genome editing in human cells with
high specificity and low cytotoxicity. Nucleic Acids Res. 42, 6762–6773. doi:
10.1093/nar/gku305
Myers, M. J., Farrell, D. E., Howard, K. D., and Kawalek, J. C. (2001). Identification
of multiple constitutive and inducible hepatic cytochrome P450 enzymes in
market weight swine. Drug Metab. Dispos. 29, 908–915.
N.C.I. Surveillance Research Program. Seer∗Stat Software
(Seer.Cancer.Gov/Seerstat) Version 4.2.0.
Nambiar, M., Kari, V., and Raghavan, S. C. (2008). Chromosomal translocations in
cancer. Biochim. Biophys. Acta 1786, 139–152. doi: 10.1016/j.bbcan.2008.07.005
Ogle, K. S., Swanson, G. M., Woods, N., and Azzouz, F. (2000). Cancer
and comorbidity: redefining chronic diseases. Cancer 88, 653–663. doi:
10.1002/(SICI)1097-0142(20000201)88:3<653::AID-CNCR24>3.0.CO;2-1
Oxenhandler, R. W., Adelstein, E. H., Haigh, J. P., Hook, R. R. Jr., and Clark, W.
H. Jr. (1979). Malignant melanoma in the sinclair miniature swine: an autopsy
study of 60 cases. Am. J. Pathol. 96, 707–720.
Oxenhandler, R. W., Berkelhammer, J., Smith, G. D., and Hook, R. R. Jr. (1982).
Growth and regression of cutaneous melanomas in sinclair miniature swine.
Am. J. Pathol. 109, 259–269.
Pabo, C. O., Peisach, E., and Grant, R. A. (2001). Design and selection of
novel Cys2his2 zinc finger proteins. Annu. Rev. Biochem. 70, 313–340. doi:
10.1146/annurev.biochem.70.1.313
Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer
immunotherapy. Nat. Rev. Cancer 12, 252–264. doi: 10.1038/nrc3239
Pasmant, E., Sabbagh, A., Spurlock, G., Laurendeau, I., Grillo, E., Hamel, M. J.,
et al. (2010). Nf1 microdeletions in neurofibromatosis type 1: from genotype to
phenotype. Hum. Mutat. 31, E1506–E1518. doi: 10.1002/humu.21271
Petursdottir, T. E., Thorsteinsdottir, U., Jonasson, J. G., Moller, P. H., Huiping,
C., Bjornsson, J., et al. (2004). Interstitial deletions including chromosome
3 common eliminated region 1 (C3cer1) prevail in human solid tumors
from 10 different tissues. Genes Chromosomes Cancer 41, 232–242. doi:
10.1002/gcc.20072
Piganeau, M., Ghezraoui, H., De Cian, A., Guittat, L., Tomishima, M., Perrouault,
L., et al. (2013). Cancer translocations in human cells induced by zinc
finger and tale nucleases. Genome Res. 23, 1182–1193. doi: 10.1101/gr.
147314.112
Prather, R. S., Shen, M., and Dai, Y. (2008). Genetically modified pigs for
medicine and agriculture. Biotechnol. Genet. Eng. Rev. 25, 245–265. doi:
10.1002/mrd.21333
Rangarajan, A., and Weinberg, R. A. (2003). Opinion: comparative biology of
mouse versus human cells: modelling human cancer in mice. Nat. Rev. Cancer
3, 952–959. doi: 10.1038/nrc1235
Renan, M. J. (1993). How many mutations are required for tumorigenesis?
implications from human cancer data. Mol. Carcinog. 7, 139–146. doi:
10.1002/mc.2940070303
Restifo, N. P., Dudley, M. E., and Rosenberg, S. A. (2012). Adoptive
immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol.
12, 269–281. doi: 10.1038/nri3191
Rosenberg, S. A. (1984). Adoptive immunotherapy of cancer: accomplishments
and prospects. Cancer Treat. Rep. 68, 233–255.
Roth, W. J., Kissinger, C. B., McCain, R. R., Cooper, B. R., Marchant-Forde, J. N.,
Vreeman, R. C., et al. (2013). Assessment of juvenile pigs to serve as human
pediatric surrogates for preclinical formulation pharmacokinetic testing. AAPS
J. 15, 763–774. doi: 10.1208/s12248-013-9482-6
Schook, L. B., Beever, J. E., Rogers, J., Humphray, S., Archibald, A., Chardon,
P., et al. (2005). Swine Genome Sequencing Consortium (SGSC): a strategic
roadmap for sequencing the pig genome. Comp. Funct. Genomics 6, 251–255.
doi: 10.1002/cfg.479
Schook, L. B., Collares, T. V., Hu, W., Liang, Y., Rodrigues, F. M., Rund, L. A.,
et al. (2015). A genetic porcine model of cancer. PLoS ONE 10:e0128864. doi:
10.1371/journal.pone.0128864
Schook, L. B., Kuzmuk, K., Adam, S., Rund, L., Chen, K., Rogatcheva, M.,
et al. (2008). DNA-based animal models of human disease: from genotype to
phenotype. Dev. Biol. (Basel). 132, 15–25. doi: 10.1159/000317140
Schook, L. B., Rund, L., Begnini, K. R., Remiao, M. H., Seixas, F. K., and Collares,
T. (2016). Emerging technologies to create inducible and genetically defined
porcine cancer models. Front. Genet. 7:28. doi: 10.3389/fgene.2016.00028
Shin, J., Chen, J., and Solnica-Krezel, L. (2014). Efficient homologous
recombination-mediated genome engineering in zebrafish using tale nucleases.
Development 141, 3807–3818. doi: 10.1242/dev.108019
Shultz, L. D., Ishikawa, F., and Greiner, D. L. (2007). Humanized mice
in translational biomedical research. Nat. Rev. Immunol. 7, 118–130. doi:
10.1038/nri2017
Siegel, R., Naishadham, D., and Jemal, A. (2012). Cancer statistics, 2012.CACancer
J. Clin. 62, 10–29. doi: 10.3322/caac.20138
Sieren, J. C., Meyerholz, D. K., Wang, X. J., Davis, B. T., Newell, J. D. Jr.,
Hammond, E., et al. (2014). Development and translational imaging of a Tp53
porcine tumorigenesis model. J. Clin. Invest. 124, 4052–4066. doi: 10.1172/jci
75447
Sinkora, M., Sinkora, J., Rehakova, Z., and Butler, J. E. (2000). Early ontogeny of
thymocytes in pigs: sequential colonization of the thymus by T cell progenitors.
J. Immunol. 165, 1832–1839. doi: 10.4049/jimmunol.165.4.1832
Sjoblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D.,
et al. (2006). The consensus coding sequences of human breast and colorectal
cancers. Science 314, 268–274. doi: 10.1126/science.1133427
Sogaard, M., Thomsen, R. W., Bossen, K. S., Sorensen, H. T., and Norgaard, M.
(2013). The impact of comorbidity on cancer survival: a review.Clin. Epidemiol.
5, 3–29. doi: 10.2147/CLEP.S47150
Suzuki, S., Iwamoto, M., Saito, Y., Fuchimoto, D., Sembon, S., Suzuki, M., et al.
(2012). Il2rg gene-targeted severe combined immunodeficiency pigs. Cell Stem
Cell 10, 753–758. doi: 10.1016/j.stem.2012.04.021
Swanson, K. S., Mazur, M. J., Vashisht, K., Rund, L. A., Beever, J. E., Counter, C.
M., et al. (2004). Genomics and clinical medicine: rationale for creating and
effectively evaluating animal models. Exp. Biol. Med. (Maywood). 229, 866–875.
Swindle, M. M., Makin, A., Herron, A. J., Clubb, F. J. Jr., and Frazier, K. S. (2012).
Swine as models in biomedical research and toxicology testing. Vet. Pathol. 49,
344–356. doi: 10.1177/0300985811402846
Tan, W., Carlson, D. F., Lancto, C. A., Garbe, J. R., Webster, D. A., Hackett, P.
B., et al. (2013). Efficient nonmeiotic allele introgression in livestock using
custom endonucleases. Proc. Natl. Acad. Sci. U.S.A. 110, 16526–16531. doi:
10.1073/pnas.1310478110
Tan, W. S., Carlson, D. F., Walton, M. W., Fahrenkrug, S. C., and Hackett, P. B.
(2012). Precision editing of large animal genomes. Adv. Genet. 80, 37–97. doi:
10.1016/B978-0-12-404742-6.00002-8
Taneja, P., Zhu, S., Maglic, D., Fry, E. A., Kendig, R. D., and Inoue, K.
(2011). Transgenic and knockout mice models to reveal the functions
Frontiers in Genetics | www.frontiersin.org 15 May 2016 | Volume 7 | Article 78
Watson et al. Engineered Swine Models of Cancer
of tumor suppressor genes. Clin. Med. Insights Oncol. 5, 235–257. doi:
10.4137/CMO.S7516
Thiagalingam, S., Laken, S., Willson, J. K., Markowitz, S. D., Kinzler, K. W.,
Vogelstein, B., et al. (2001). Mechanisms underlying losses of heterozygosity
in human colorectal cancers. Proc. Natl. Acad. Sci. U.S.A. 98, 2698–2702. doi:
10.1073/pnas.051625398
Tschida, B. R., Largaespada, D. A., and Keng, V. W. (2014). Mouse
models of cancer: sleeping beauty transposons for insertional mutagenesis
screens and reverse genetic studies. Semin. Cell Dev. Biol. 27, 86–95. doi:
10.1016/j.semcdb.2014.01.006
Vilahur, G., Padro, T., and Badimon, L. (2011). Atherosclerosis and thrombosis:
insights from large animal models. J. Biomed. Biotechnol. 2011:907575. doi:
10.1155/2011/907575
Watanabe, M., Nakano, K., Matsunari, H., Matsuda, T., Maehara, M., Kanai,
T., et al. (2013). Generation of interleukin-2 receptor gamma gene knockout
pigs from somatic cells genetically modified by zinc finger nuclease-encoding
mRNA. PLoS ONE 8:e76478. doi: 10.1371/journal.pone.0076478
Wei, J., Wagner, S., Lu, D., Maclean, P., Carlson, D. F., Fahrenkrug, S. C., et al.
(2015). Efficient introgression of allelic variants by embryo-mediated editing of
the bovine genome. Sci. Rep. 5:11735. doi: 10.1038/srep11735
Whitworth, K. M., Lee, K., Benne, J. A., Beaton, B. P., Spate, L. D., Murphy, S. L.,
et al. (2014). Use of the Crispr/Cas9 system to produce genetically engineered
pigs from in vitro-derived oocytes and embryos. Biol. Reprod. 91, 78. doi:
10.1095/biolreprod.114.121723
Wiesner, S. M., Decker, S. A., Larson, J. D., Ericson, K., Forster, C., Gallardo, J. L.,
et al. (2009). De novo induction of genetically engineered brain tumors in mice
using plasmid DNA. Cancer Res. 69, 431–439. doi: 10.1158/0008-5472.CAN-
08-1800
Yamakawa, H., Nagai, T., Harasawa, R., Yamagami, T., Takahashi, J., Ishikawa,
K.-I., et al. (1999). Production of transgenic pig carrying Mmtv/V-Ha-Ras. J.
Reprod. Dev. 45, 111–118.
Zanjani, E. D., Ascensao, J. L., Flake, A. W., Harrison, M. R., and Tavassoli, M.
(1992a). The fetus as an optimal donor and recipient of hemopoietic stem cells.
Bone Marrow Transplant. 10(Suppl. 1), 107–114.
Zanjani, E. D., Flake, A. W., Rice, H., Hedrick, M., and Tavassoli, M. (1994).
Long-term repopulating ability of xenogeneic transplanted human fetal liver
hematopoietic stem cells in sheep. J. Clin. Invest. 93, 1051–1055. doi:
10.1172/jci117054
Zanjani, E. D., Pallavicini, M. G., Ascensao, J. L., Flake, A. W., Langlois, R. G.,
Reitsma, M., et al. (1992b). Engraftment and long-term expression of human
fetal hemopoietic stem cells in sheep following transplantation in utero. J. Clin.
Invest. 89, 1178–1188. doi: 10.1172/jci115701
Zitvogel, L., Kepp, O., and Kroemer, G. (2011). Immune parameters affecting the
efficacy of chemotherapeutic regimens. Nat. Rev. Clin. Oncol. 8, 151–160. doi:
10.1038/nrclinonc.2010.223
Conflict of Interest Statement: All authors are owners and employees of
Recombinetics Inc. Additionally, DL is a consultant, co-founder, and equity
holder of NeoClone Biotechnology, Inc., a company providing antibodies to
it’s customers. DL is a consultant, co-founder, and equity holder of Discovery
Genomics, Inc., a company pursuing human gene therapy. DL is a consultant, co-
founder, and equity holder of B-MoGen Biotechnologies, Inc., a gene delivery and
gene editing company. DL has a collaborative research agreements with Novartis
and Genentech. Genentech is funding a research project DL’s laboratory.
Copyright © 2016 Watson, Carlson, Largaespada, Hackett and Fahrenkrug. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Genetics | www.frontiersin.org 16 May 2016 | Volume 7 | Article 78
